Celcuity Inc. (CELC)
Oxford Ledge is still expanding full research coverage of CELC. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Clinical-stage biotech developing gedatolisib, a PAM pathway inhibitor, with multiple Phase 3 trials underway in breast and prostate cancers.
SEC filings
- 8-K Entry into material agreement; Termination of material agreement; Creation of direct financial obligation; Other material event; Financial statements and exhibits 2026-06-08
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-02
- 8-K Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-05-18
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-14
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for CELC. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CELC in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.